Anti-Viral Drugs Market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Report Description<br />
• Herpes antivirals<br />
• Hepatitis-B antivirals<br />
• Influenza antivirals<br />
• Others (Pneumonia, Flu, etc.)<br />
Based on end user, the global anti-viral drugs market is segmented into the following:<br />
• Hospitals<br />
• Clinics<br />
• Ambulatory Surgical Centers<br />
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1951<br />
<strong>Anti</strong>-viral <strong>Drugs</strong> <strong>Market</strong>: Overview<br />
The generic market of anti-viral drugs is presently dominated by products such as<br />
didanosine, zidovudine, lamivudine and stavudine. The biggest driver of overall anti-viral<br />
drugs market is Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome<br />
(HIV/AIDS) therapeutic sales which accounted for more than half the share of the market<br />
2010. At the end of 2012, 9.7 million people in low-income and middle-income countries<br />
were on antiretroviral treatment (ART). According to WHO, in 2012, number of patients<br />
on ART increased by 1.6 Mn, the largest increase in one year. Nearly four out of five
Change language